As NVIDIA Blog outlines, BMS's expansion is less about raw compute power and more about democratizing access across its scientific workforce. The critical challenge, which the announcement acknowledges but cannot guarantee to solve, is operationalizing this infrastructure to consistently improve R&D outcomes. In our view, the success of such 'AI factories' hinges not on the hardware but on the quality of internal data, the usability of the tooling for bench scientists, and the organization's ability to integrate AI workflows into established, heavily regulated development processes. The industry will be watching to see if BMS can move from impressive compute metrics to a demonstrable impact on its drug pipeline.